Clinical Trials in Eugene, Oregon

80 recruiting

Showing 120 of 79 trials

Recruiting
Phase 3

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Chronic Lymphocytic LeukemiaCLL
BeOne Medicines250 enrolled112 locationsNCT06846671
Recruiting
Phase 2Phase 3

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Advanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer
Mirati Therapeutics Inc.806 enrolled764 locationsNCT04613596
Recruiting
Phase 2Phase 3

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Multiple Myeloma
AbbVie660 enrolled25 locationsNCT07095452
Recruiting
Phase 3

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines630 enrolled155 locationsNCT06943872
Recruiting
Phase 2

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)

Colorectal, CancerColon CancerRectal Cancer+1 more
SCRI Development Innovations, LLC60 enrolled14 locationsNCT07011576
Recruiting
Phase 3

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Low Grade Serous Ovarian Cancer
Verastem, Inc.270 enrolled106 locationsNCT06072781
Recruiting
Phase 2

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Large B-cell Lymphoma
Allogene Therapeutics250 enrolled61 locationsNCT06500273
Recruiting
Phase 2

Study of Novel Treatment Combinations in Patients With Lung Cancer

Lung CancerAdvanced or Metastatic Non-small Cell Lung CancerResectable Non-small Cell Lung Cancer
Gilead Sciences270 enrolled100 locationsNCT05633667
Recruiting
Phase 2

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

Colorectal Cancer Stage IIIColorectal Cancer Stage II
BioNTech SE327 enrolled121 locationsNCT04486378
Recruiting
Phase 3

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Ovarian Cancer
Incyte Corporation466 enrolled133 locationsNCT07214779
Recruiting
Phase 3

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Cervical Cancer
Merck Sharp & Dohme LLC686 enrolled239 locationsNCT06459180
Recruiting
Phase 2

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

Small Lymphocytic LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Janssen Research & Development, LLC320 enrolled73 locationsNCT05963074
Recruiting
Phase 3

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Endometrial Cancer
Merck Sharp & Dohme LLC1,123 enrolled232 locationsNCT06952504
Recruiting
Phase 3

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Multiple Myeloma
Bristol-Myers Squibb1,216 enrolled285 locationsNCT05827016
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Merck Sharp & Dohme LLC770 enrolled125 locationsNCT06824467
Recruiting
Phase 3

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer MetastaticNon-Small-Cell Lung CarcinomaNon-small Cell Carcinoma
Pfizer680 enrolled253 locationsNCT07144280
Recruiting
Phase 3

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Endometrial Cancer
AstraZeneca600 enrolled249 locationsNCT06989112
Recruiting
Phase 3

A Long-term Extension Study of PCI-32765 (Ibrutinib)

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled174 locationsNCT01804686
Recruiting
Phase 3

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Acute Myeloid Leukemia (AML)
Kura Oncology, Inc.1,300 enrolled29 locationsNCT07007312
Recruiting
Phase 3

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Carcinoma, Non-Small Cell LungNeoplasm Metastasis
Eli Lilly and Company1,264 enrolled424 locationsNCT06119581